Premium
FK506 and cyclosporin a regulate proliferation and proto‐oncogene expression in HTLV‐1 ‐associated myelopathy/tropical‐spastic‐paraparesis‐derived T cells
Author(s) -
Natazuka Toshiki,
UmemiyaOkada Tomoyo,
Matsui Toshimitsu,
Nakao Yoshinobu,
Saida Takahiko
Publication year - 1993
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910540230
Subject(s) - tropical spastic paraparesis , myelopathy , cancer research , oncogene , medicine , immunology , biology , neuroscience , cancer , spinal cord , cell cycle
Human T‐cell‐leukemia‐virus‐type‐1 (HTLV‐I) infection is associated with adult T‐cell leukemia/lymphoma (ATL) and HTLV‐1 ‐associated myelopathy (HAM)/tropical spastic paraparesis (TSP). The T‐cell‐targeting immunosuppressants, FK506 and cyclosporin A (CsA), suppressed proliferation of the HAM/TSP‐derived T‐cell lines, H89–59, H89–79 and H109. FK506 and CsA also reduced expression of the proto‐oncogenes, c‐myc and c‐fos, but not c‐jun and interleukin‐2‐receptor‐α (IL‐2Rα) gene in H109 cells. The growth‐inhibitory effects of FKS06 and CsA were not abrogated by interleukin 2 (IL‐2). These results suggest that the inhibitory effects of FK506 and CsA are independent of IL‐2, and are associated with the reduction of c‐myc and c‐fos gene expression.